Published in Cancer Weekly, September 15th, 1997
ISSs not only add potent cellular immune responses to the antibody responses elicited by inactivated or subunit vaccines, but also suppress the IgE responses that sometimes lead to vaccine fatalities.
"The co-administration of ISS-DNAs with a conventional vaccine not only markedly augments antibody production but also activates cell-mediated immunity," wrote Mark Roman of Dynavax Technologies Corp., San Diego, California, and colleagues. "Protein/ISS-DNA combinations might thus constitute optimal vaccines with which to combat infectious...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.